Gemcitabine - Eli Lilly and Company/Genentech
Alternative Names: dFdC; dFdCTP; Gemcitabine Hydrochloride; Gemtro; Gemzar; LY-188011Latest Information Update: 15 Oct 2024
At a glance
- Originator Eli Lilly and Company; Genentech; University of Innsbruck
- Developer AstraZeneca; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Eli Lilly and Company; Genentech; Mayo Clinic; National Cancer Institute (USA); University of Iowa
- Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
- Mechanism of Action Antimetabolites; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
- Phase III Cervical cancer
- Phase II Cholangiocarcinoma; Lymphoma; Renal cell carcinoma
- No development reported Head and neck cancer; Sarcoma; Solid tumours
Most Recent Events
- 03 Oct 2024 Cheplapharm acquires worldwide (except South Korea) rights to Gemcitabine from Eli Lilly and Company
- 21 Aug 2023 Phase-II clinical trials in Cholangiocarcinoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT05655949)
- 06 Jan 2020 No development reported - Phase-I/II for Sarcoma (Combination therapy, First-line therapy, In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults) in USA (IV) (Eli-Lilly pipeline, January 2020)